Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma

Nivolumab is a programmed death receptor 1 (PD-1) inhibitor. It is part of a group of drugs known as immune checkpoint blockers, which enable potent and durable T-cell responses against several tumors. We report the case of a patient with a metastatic squamous cell carcinoma, who is being treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Oro-Ayude, Marcos, Suh-Oh, Hae Jin, Sacristán-Santos, Victor, Vázquez-Bartolomé, Patricia, Flórez, Ángeles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315375/
https://www.ncbi.nlm.nih.gov/pubmed/32595466
http://dx.doi.org/10.1159/000505478
_version_ 1783550245586599936
author Oro-Ayude, Marcos
Suh-Oh, Hae Jin
Sacristán-Santos, Victor
Vázquez-Bartolomé, Patricia
Flórez, Ángeles
author_facet Oro-Ayude, Marcos
Suh-Oh, Hae Jin
Sacristán-Santos, Victor
Vázquez-Bartolomé, Patricia
Flórez, Ángeles
author_sort Oro-Ayude, Marcos
collection PubMed
description Nivolumab is a programmed death receptor 1 (PD-1) inhibitor. It is part of a group of drugs known as immune checkpoint blockers, which enable potent and durable T-cell responses against several tumors. We report the case of a patient with a metastatic squamous cell carcinoma, who is being treated with nivolumab. This patient achieved a complete response and continues treatment without progression signs, supporting the notion that PD-1 inhibition can induce long-term remission and is well tolerated in this type of patient.
format Online
Article
Text
id pubmed-7315375
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-73153752020-06-26 Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma Oro-Ayude, Marcos Suh-Oh, Hae Jin Sacristán-Santos, Victor Vázquez-Bartolomé, Patricia Flórez, Ángeles Case Rep Dermatol Single Case Nivolumab is a programmed death receptor 1 (PD-1) inhibitor. It is part of a group of drugs known as immune checkpoint blockers, which enable potent and durable T-cell responses against several tumors. We report the case of a patient with a metastatic squamous cell carcinoma, who is being treated with nivolumab. This patient achieved a complete response and continues treatment without progression signs, supporting the notion that PD-1 inhibition can induce long-term remission and is well tolerated in this type of patient. S. Karger AG 2020-02-12 /pmc/articles/PMC7315375/ /pubmed/32595466 http://dx.doi.org/10.1159/000505478 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Oro-Ayude, Marcos
Suh-Oh, Hae Jin
Sacristán-Santos, Victor
Vázquez-Bartolomé, Patricia
Flórez, Ángeles
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
title Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
title_full Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
title_fullStr Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
title_full_unstemmed Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
title_short Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
title_sort nivolumab for metastatic cutaneous squamous cell carcinoma
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315375/
https://www.ncbi.nlm.nih.gov/pubmed/32595466
http://dx.doi.org/10.1159/000505478
work_keys_str_mv AT oroayudemarcos nivolumabformetastaticcutaneoussquamouscellcarcinoma
AT suhohhaejin nivolumabformetastaticcutaneoussquamouscellcarcinoma
AT sacristansantosvictor nivolumabformetastaticcutaneoussquamouscellcarcinoma
AT vazquezbartolomepatricia nivolumabformetastaticcutaneoussquamouscellcarcinoma
AT florezangeles nivolumabformetastaticcutaneoussquamouscellcarcinoma

Ejemplares similares